CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-08 | Pelzer Robert Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2017-05-08 | LEVITT DANIEL J Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2017-05-08 | Bridger Gary Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2017-05-08 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2017-03-08 | Troupin Barbara Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2017-03-08 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2017-03-08 | McCloskey Shelley VP, HR and Administration | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2017-03-08 | Main David President and CEO | Grant or award · Stock Option (Right to Buy) | +185,000 | 185,000 | ||
| 2017-03-08 | MacKenzie Lloyd VP Technical Operations | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2017-03-08 | Jenkins Abigail Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2017-03-08 | Alam Kamran CFO, Vice President Finance | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +603 | $16.74 | $10K | 1,132,228 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +5,697 | $16.74 | $95K | 9,410,164 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +1,195 | $15.32 | $18K | 1,133,423 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +11,305 | $15.32 | $173K | 9,421,469 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +258 | $16.85 | $4K | 1,133,681 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +2,442 | $16.85 | $41K | 9,423,911 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +917 | $15.35 | $14K | 1,134,598 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +8,671 | $15.35 | $133K | 9,432,582 |
| 2017-01-09 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +967 | $16.20 | $16K | 1,135,565 |
Page 15 of 20 · 397 trades